Evaluation of PIK3CA mutation as a predictor of benefit from NSAID therapy in colorectal cancer

Podobne zapisy

• Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
  od: Domingo, E, i wsp.
  Wydane: (2013)
• Are NSAIDs Coming Back to Colorectal Cancer Therapy or Not?
  od: Herbert, K, i wsp.
  Wydane: (2014)
• PIK3CA Mutation is Strongly Associated with K-ras 12/13 Mutation in Stage II/III Colorectal Cancer
  od: Southward, K, i wsp.
  Wydane: (2012)
• PIK3CA in colorectal cancer
  od: Gieri eCathomas
  Wydane: (2014-03-01)
• Determination of the frequency and distribution of APC, PIK3CA, and SMAD4 gene mutations in Ugandan patients with colorectal cancer
  od: Wismayer, R, i wsp.
  Wydane: (2024)